Pooja Mohan Rao, MD
Neurology · New Orleans, LANPI 1750638508
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by UCB, Inc. at 52.9% of the total. Reporting peaked in 2023 at $8,314 and has fallen 78.4% since, to $1,794 in 2025.
Across 140 payments — averaging $121.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$9K
- Grifols USA, LLC$3K
- Neuropace, Inc.$1K
- Biogen$531
- Teva Pharmaceuticals USA, Inc.$483
- AbbVie$370
- plus $2K from 24 others
What the payments were for
- Consulting fees$1,98012%
- Speaking & faculty fees$7,14042%
- Travel & lodging$3,43120%
- Food & beverage$4,04124%
- Education$3492%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 13 | $8,955 |
| Grifols USA, LLC | 8 | $3,092 |
| Neuropace, Inc. | 4 | $1,392 |
| Biogen | 11 | $531 |
| Teva Pharmaceuticals USA, Inc. | 16 | $483 |
| AbbVie(2 entities) | 18 | $370 |
| Merz Pharmaceuticals, LLC | 12 | $295 |
| GE HealthCare | 9 | $263 |
| Argenx US, Inc. | 5 | $193 |
| Amneal Pharmaceuticals LLC | 8 | $162 |
| Baxter Healthcare | 1 | $131 |
| Kyowa Kirin, Inc. | 6 | $130 |
| Tandem Diabetes Care, Inc. | 1 | $119 |
| Alnylam Pharmaceuticals Inc. | 1 | $102 |
| Sarepta Therapeutics, Inc. | 1 | $92 |
| Novartis | 1 | $92 |
| Neurocrine Biosciences, Inc. | 4 | $91 |
| Acorda Therapeutics, Inc | 4 | $73 |
| Corium, LLC | 2 | $48 |
| Azurity Pharmaceuticals, Inc. | 2 | $44 |
| Acadia Pharmaceuticals Inc | 2 | $43 |
| Avion Pharmaceuticals | 2 | $41 |
| Abbott | 2 | $37 |
| SK Life Science, Inc. | 1 | $37 |
| AstraZeneca | 1 | $28 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Eisai Inc. | 1 | $22 |
| Ascensia Diabetes Care US Inc. | 1 | $19 |
| Amgen | 1 | $17 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rystiggo$8,669
- Gamunex-C$2,944
- RNS System$1,327
- TISSEEL$131
- t:slim X2 Insulin Pump with Control-IQ$119
- ONPATTRO$102
How this compares
$16,941 in reported general payments places this provider in the 80th percentile of 225 neurology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 22 | $312,261 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 13 | $141,977 |
| Riluzole | 13 | $878 |
| Gabapentin | 47 | $669 |
| Duloxetine Hcl | 14 | $411 |
| Pregabalin | 15 | $342 |
| Tramadol Hcl | 13 | $47 |
Paid to pharmacies, not to this prescriber.
Other neurology in New Orleans
- John EnglandNew Orleans$268K
- Brian CopelandNew Orleans$211K
- Bridget BagertNew Orleans$198K
- Sheryl Martin-SchildNew Orleans$106K
- Piotr OlejniczakNew Orleans$82K
- Elizabeth CrabtreeNew Orleans$36K
- Caroline GoldinNew Orleans$36K
- Jesus LoveraNew Orleans$27K
- Julia StaischNew Orleans$22K
- Ronald FioreNew Orleans$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.